Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This phase I/II trial studies the side effects and best dose of temozolomide and M1774 and how well they works in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and may have spread to nearby tissue, lymph nodes, or distant parts of the body (advanced). Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow down or stop tumor growth. M1774 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Adding M1774 to temozolomide may shrink or stabilize cancer for longer than temozolomide alone.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Potwierdzony diagnoza zaawansowanego raka, który rozprzestrzenił się na inne części ciała
  • Brak wcześniejszego leczenia temozolomidem lub lekami hamującymi ATR
  • Wcześniejsze leczenie nie przyniosło poprawy lub pacjent nie toleruje standardowych leków
  • W fazie drugiej badania: rak jelita grubego ze zmianami genetycznymi MGMT w archiwalnych próbkach tkanek

✗ Disqualifies

  • Wcześniejsza ciężka alergiczna reakcja na jeden z leków chemicznych stosowanych w badaniu

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 16, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (23)

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Irvine, United States

UC San Diego Moores Cancer Center

La Jolla, United States

UC Irvine Health/Chao Family Comprehensive Cancer Center

Orange, United States

Yale University

New Haven, United States

Smilow Cancer Hospital Care Center-Trumbull

Trumbull, United States

Memorial Hospital East

Shiloh, United States

University of Kansas Clinical Research Center

Fairway, United States

University of Kansas Cancer Center

Kansas City, United States

University of Kansas Cancer Center-Overland Park

Overland Park, United States

University of Kansas Hospital-Indian Creek Campus

Overland Park, United States

University of Kansas Hospital-Westwood Cancer Center

Westwood, United States

National Cancer Institute Developmental Therapeutics Clinic

Bethesda, United States

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, United States

Siteman Cancer Center at West County Hospital

Creve Coeur, United States

University of Kansas Cancer Center - North

Kansas City, United States

University of Kansas Cancer Center - Lee's Summit

Lee's Summit, United States

University of Kansas Cancer Center at North Kansas City Hospital

North Kansas City, United States

Washington University School of Medicine

St Louis, United States

Siteman Cancer Center-South County

St Louis, United States

Siteman Cancer Center at Christian Hospital

St Louis, United States

University of Oklahoma Health Sciences Center

Oklahoma City, United States

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, United States

Vanderbilt University/Ingram Cancer Center

Nashville, United States

Trial contact

Site Public Contact

Farshid Dayyani

PRINCIPAL_INVESTIGATOR

Michael Cecchini

PRINCIPAL_INVESTIGATOR

Raed Al-Rajabi

PRINCIPAL_INVESTIGATOR

Site Public Contact

A P. Chen

PRINCIPAL_INVESTIGATOR

Abdul Rafeh Naqash

PRINCIPAL_INVESTIGATOR

Site Public Contact

Janie Y. Zhang

PRINCIPAL_INVESTIGATOR

Site Public Contact

Elizabeth J. Davis

PRINCIPAL_INVESTIGATOR

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.